Skip to main content
SpringerLink
Log in

RNA Editing Deficiency in Neurodegeneration

  • Chapter
  • First Online:
Book cover RNA Metabolism in Neurodegenerative Diseases

Part of the book series: Advances in Neurobiology ((NEUROBIOL,volume 20))

Abstract

The molecular process of RNA editing allows changes in RNA transcripts that increase genomic diversity. These highly conserved RNA editing events are catalyzed by a group of enzymes known as adenosine deaminases acting on double-stranded RNA (ADARs). ADARs are necessary for normal development, they bind to over thousands of genes, impact millions of editing sites, and target critical components of the central nervous system (CNS) such as glutamate receptors, serotonin receptors, and potassium channels. Dysfunctional ADARs are known to cause alterations in CNS protein products and therefore play a role in chronic or acute neurodegenerative and psychiatric diseases as well as CNS cancer. Here, we review how RNA editing deficiency impacts CNS function and summarize its role during disease pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature. 1999;399(6731):75–80.

    Article  PubMed  CAS  Google Scholar 

  2. Gerber AP, Keller W. RNA editing by base deamination: more enzymes, more targets, new mysteries. Trends Biochem Sci. 2001;26(6):376–84.

    Article  PubMed  CAS  Google Scholar 

  3. Paul MS, Bass BL. Inosine exists in mRNA at tissue-specific levels and is most abundant in brain mRNA. EMBO J. 1998;17(4):1120–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Gal-Mark N, et al. Abnormalities in A-to-I RNA editing patterns in CNS injuries correlate with dynamic changes in cell type composition. Sci Rep. 2017;7:43421.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lee SY, et al. RCARE: RNA sequence comparison and annotation for RNA editing. BMC Med Genomics. 2015;8(Suppl 2):S8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Gu T, et al. Canonical A-to-I and C-to-U RNA editing is enriched at 3′UTRs and microRNA target sites in multiple mouse tissues. PLoS One. 2012;7(3):e33720.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Kim DD, et al. Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res. 2004;14(9):1719–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Yang JH, et al. Intracellular localization of differentially regulated RNA-specific adenosine deaminase isoforms in inflammation. J Biol Chem. 2003;278(46):45833–42.

    Article  PubMed  CAS  Google Scholar 

  9. Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol. 1995;15(10):5376–88.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Wang Q, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem. 2004;279(6):4952–61.

    Article  PubMed  CAS  Google Scholar 

  11. Hartner JC, et al. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem. 2004;279(6):4894–902.

    Article  PubMed  CAS  Google Scholar 

  12. Yao L, et al. Large-scale prediction of ADAR-mediated effective human A-to-I RNA editing. Brief Bioinform. 2017;PMID:28968662.

    Google Scholar 

  13. Higuchi M, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406(6791):78–81.

    Article  PubMed  CAS  Google Scholar 

  14. Chen CX, Cho DS, Wang Q, Lai F, Carter KC, Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA. 2000;6:755–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Galipon J, et al. Differential binding of three major human ADAR isoforms to coding and long non-coding transcripts. Genes (Basel). 2017;8(2):pii:E68.

    Article  CAS  Google Scholar 

  16. Oakes E, et al. Adenosine deaminase that acts on RNA 3 (ADAR3) binding to glutamate receptor subunit B pre-mRNA inhibits RNA editing in glioblastoma. J Biol Chem. 2017;292(10):4326–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran DP, Jonak GJ, Hartig PR. Messenger RNA editing of the human serotonin 5-HT 2C receptor. Europsychopharmacology. 1999;21(2S):82S–90S.

    Article  CAS  Google Scholar 

  18. Bazak L, et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014;24(3):365–76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Ramaswami G, et al. Identifying RNA editing sites using RNA sequencing data alone. Nat Methods. 2013;10(2):128–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Ramaswami G, et al. Accurate identification of human Alu and non-Alu RNA editing sites. Nat Methods. 2012;9(6):579–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Neeman Y, et al. RNA editing level in the mouse is determined by the genomic repeat repertoire. RNA. 2006;12(10):1802–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Rodriguez J, Menet JS, Rosbash M. Nascent-seq indicates widespread cotranscriptional RNA editing in drosophila. Mol Cell. 2012;47(1):27–37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Levanon EY, et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol. 2004;22(8):1001–5.

    Article  PubMed  CAS  Google Scholar 

  24. Blow M, et al. A survey of RNA editing in human brain. Genome Res. 2004;14(12):2379–87.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004;2(12):e391.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Tan MH, et al. Dynamic landscape and regulation of RNA editing in mammals. Nature. 2017;550(7675):249–54.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bahn JH, et al. Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways. Nat Commun. 2015;6:6355.

    Article  PubMed  CAS  Google Scholar 

  28. Korenberg JR, Rykowski MC. Human genome Orginazation: alu, lines, and the molecular structure of metaphase chromosome bands. Cell. 1988;53:391–400.

    Article  PubMed  CAS  Google Scholar 

  29. Yablonovitch AL, et al. The evolution and adaptation of A-to-I RNA editing. PLoS Genet. 2017;13(11):e1007064.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Hwang T, et al. Dynamic regulation of RNA editing in human brain development and disease. Nat Neurosci. 2016;19(8):1093–9.

    Article  PubMed  CAS  Google Scholar 

  31. Higuchi M, et al. RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell. 1993;75(7):1361–70.

    Article  PubMed  CAS  Google Scholar 

  32. Burns CM, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 1997;387(6630):303–8.

    Article  PubMed  CAS  Google Scholar 

  33. Henley JM, Wilkinson KA. Synaptic AMPA receptor composition in development, plasticity and disease. Nat Rev Neurosci. 2016;17(6):337–50.

    Article  PubMed  CAS  Google Scholar 

  34. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. Neuron. 2013;80(3):704–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Hollmann M, Hartley M, Heinemann SF. Calcium permeability of KA-AMPA-gated glutamate receptor channels depnds on subunit composition. Science. 1991;252:851–3.

    Article  PubMed  CAS  Google Scholar 

  36. Bennett MV, et al. The GluR2 hypothesis: ca(++)-permeable AMPA receptors in delayed neurodegeneration. Cold Spring Harb Symp Quant Biol. 1996;61:373–84.

    Article  PubMed  CAS  Google Scholar 

  37. Wright A, Vissel B. The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Front Mol Neurosci. 2012;5:34.

    PubMed  PubMed Central  CAS  Google Scholar 

  38. Wenthold RJ, et al. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci. 1996;16(6):1982–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  39. Isaac JT, Ashby MC, McBain CJ. The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron. 2007;54(6):859–71.

    Article  PubMed  CAS  Google Scholar 

  40. Cull-Candy S, Kelly L, Farrant M. Regulation of Ca2+-permeable AMPA receptors: synaptic plasticity and beyond. Curr Opin Neurobiol. 2006;16(3):288–97.

    Article  PubMed  CAS  Google Scholar 

  41. Sanderson JL, Gorski JA, Dell'Acqua ML. NMDA receptor-dependent LTD requires transient synaptic incorporation of ca(2+)-permeable AMPARs mediated by AKAP150-anchored PKA and calcineurin. Neuron. 2016;89(5):1000–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010;79:321–49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Washburn MC, et al. The dsRBP and inactive editor ADR-1 utilizes dsRNA binding to regulate A-to-I RNA editing across the C. elegans transcriptome. Cell Rep. 2014;6(4):599–607.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Melcher T, et al. RED2, a brain-specific member of the RNA-specific adenosine deaminase family. J Biol Chem. 1996;271(50):31795–8.

    Article  PubMed  CAS  Google Scholar 

  45. Melcher T, et al. Editing of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR-B pre-mRNA in vitro reveals site-selective adenosine to inosine conversion. J Biol Chem. 1995;270(15):8566–70.

    Article  PubMed  CAS  Google Scholar 

  46. Sommer B, et al. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell. 1991;67(1):11–9.

    Article  PubMed  CAS  Google Scholar 

  47. Ray RS, et al. Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition. Science. 2011;333(6042):637–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Gershon MD, et al. 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology. 1990;3(5–6):385–95.

    PubMed  CAS  Google Scholar 

  49. Spencer NJ, Keating DJ. Is there a role for endogenous 5-HT in gastrointestinal motility? How recent studies have changed our understanding. Adv Exp Med Biol. 2016;891:113–22.

    Article  PubMed  CAS  Google Scholar 

  50. Hood JL, Emeson RB. Editing of neurotransmitter receptor and ion channel RNAs in the nervous system. Curr Top Microbiol Immunol. 2012;353:61–90.

    PubMed  PubMed Central  CAS  Google Scholar 

  51. Bockaert J, et al. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006;326(2):553–72.

    Article  PubMed  CAS  Google Scholar 

  52. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46(2):157–203.

    PubMed  CAS  Google Scholar 

  53. McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther. 2015;150:129–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Helton L, Thor KB, Baez M. 5-Hydroxytryptamine2A, 5-hydroxytryptamine2B, and 5-hydroxytryptamine2C receptor mRNA expression in the spinal cord of rat, cat, monkey and human. Mol Neurosci. 1994;5:2617–20.

    CAS  Google Scholar 

  55. Iwamoto K, et al. Measuring RNA editing of serotonin 2C receptor. Biochemistry (Mosc). 2011;76(8):912–4.

    Article  CAS  Google Scholar 

  56. Price RD, et al. RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J Biol Chem. 2001;276(48):44663–8.

    Article  PubMed  CAS  Google Scholar 

  57. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem. 1999;274(14):9472–8.

    Article  PubMed  CAS  Google Scholar 

  58. Sanders-Bush E, Price RD. RNA editing of the human serotonin 5-HT2C receptor delays agonist-stimulated calcium release. Mol Pharmacol. 2000;58(4):859–62.

    Article  PubMed  Google Scholar 

  59. Coetzee WA, Amarillo Y, Chiu J, Chow A, Lau D, McCormack T, Moreno H, Nadal MS, Ozaita A, Pountney D, Saganich M, Vega-Saenz de Miera E, Rudy B. Molecular diversity of K+ channels. Ann N Y Acad Sci. 1999;868:233–85.

    Article  PubMed  CAS  Google Scholar 

  60. Tian C, et al. Potassium channels: structures, diseases, and modulators. Chem Biol Drug Des. 2014;83(1):1–26.

    Article  PubMed  CAS  Google Scholar 

  61. Wang H, Kunkel DD, Schwartzkroin PA, Tempel BL. Localization of Kv1.1 and Kv1.2, two K channel proteins, to synaptic terminals, somata, and dendrites in the mouse brain. J Neurosci. 1994;14(8):4588–99.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  62. Robbins CA, Tempel BL. Kv1.1 and Kv1.2: similar channels, different seizure models. Epilepsia. 2012;53(Suppl 1):134–41.

    Article  PubMed  CAS  Google Scholar 

  63. Bhalla T, et al. Control of human potassium channel inactivation by editing of a small mRNA hairpin. Nat Struct Mol Biol. 2004;11(10):950–6.

    Article  PubMed  CAS  Google Scholar 

  64. Rettig J, Heinemann SH, Wunder F, Lorra C, Parcej DN, Dolly JO, Pongs O. Inactivation properties of voltage-gated K+ channels altered by presence of beta-subunit. Nature. 1994;369(6478):289–94.

    Article  PubMed  CAS  Google Scholar 

  65. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203.

    Article  PubMed  CAS  Google Scholar 

  66. Area-Gomez E, Schon EA. Alzheimer disease. Adv Exp Med Biol. 2017;997:149–56.

    Article  PubMed  Google Scholar 

  67. Calderon-Garciduenas AL, Duyckaerts C. Alzheimer disease. Handb Clin Neurol. 2017;145:325–37.

    Article  PubMed  Google Scholar 

  68. Akbarian S, Smith MA, Jones EG. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer’s disease, Huntington’s disease and schizophrenia. Brain Res. 1995;699(2):297–304.

    Article  PubMed  CAS  Google Scholar 

  69. Gaisler-Salomon I, et al. Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer’s disease. Neurobiol Aging. 2014;35(8):1785–91.

    Article  PubMed  CAS  Google Scholar 

  70. Payami H, et al. Apolipoprotein E genotype and Alzheimer’s disease. Lancet. 1993;342(8873):738.

    Article  PubMed  CAS  Google Scholar 

  71. Saunders AM, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43(8):1467–72.

    Article  PubMed  CAS  Google Scholar 

  72. Valastro B, et al. AMPA receptor regulation and LTP in the hippocampus of young and aged apolipoprotein E-deficient mice. Neurobiol Aging. 2001;22(1):9–15.

    Article  PubMed  CAS  Google Scholar 

  73. Cantanelli P, et al. Age-dependent modifications of AMPA receptor subunit expression levels and related cognitive effects in 3xTg-AD mice. Front Aging Neurosci. 2014;6:200.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Stilling RM, et al. De-regulation of gene expression and alternative splicing affects distinct cellular pathways in the aging hippocampus. Front Cell Neurosci. 2014;8:373.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Stilling RM, et al. K-lysine acetyltransferase 2a regulates a hippocampal gene expression network linked to memory formation. EMBO J. 2014;33(17):1912–27.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Khermesh K, et al. Reduced levels of protein recoding by A-to-I RNA editing in Alzheimer’s disease. RNA. 2016;22(2):290–302.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014;37(8):433–42.

    Article  PubMed  CAS  Google Scholar 

  78. Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197–206.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Bettencourt C, Houlden H. Exome sequencing uncovers hidden pathways in familial and sporadic ALS. Nat Neurosci. 2015;18(5):611–3.

    Article  PubMed  CAS  Google Scholar 

  80. Chien-Liang Glenn Lin LAB, Lin J, Margaret Dykes-Hoberg TC, Lora-Clawson JDR. 1-s2.0-S0896627300809976-main.Pdf. Neuron. 1998;20:589–602.

    Article  Google Scholar 

  81. Rothstein JD, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol. 1990;28(1):18–25.

    Article  PubMed  CAS  Google Scholar 

  82. Lu YM, Yin HZ, Chiang J, Weiss JH. Ca2+-permeable AMPA/Kainate and NMDA channels: high rate of Ca2+ influx underlies potent induction of injury. J Neurosci. 1996;16(17):5457–65.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  83. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996;16(13):4069–79.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  84. Takuma H, et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46(6):806–15.

    Article  PubMed  CAS  Google Scholar 

  85. Kawahara Y, et al. Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for excitotoxicity in ALS. J Neurochem. 2003;85(3):680–9.

    Article  PubMed  CAS  Google Scholar 

  86. Williams TL, et al. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1997;42(2):200–7.

    Article  PubMed  CAS  Google Scholar 

  87. Van Den Bosch L, et al. Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci. 2000;180(1–2):29–34.

    Article  Google Scholar 

  88. Morrison BM, et al. Light and electron microscopic distribution of the AMPA receptor subunit, GluR2, in the spinal cord of control and G86R mutant superoxide dismutase transgenic mice. J Comp Neurol. 1998;395(4):523–34.

    Article  PubMed  CAS  Google Scholar 

  89. Kawahara Y, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427(6977):801.

    Article  PubMed  CAS  Google Scholar 

  90. Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med (Berl). 2005;83(2):110–20.

    Article  CAS  Google Scholar 

  91. Hideyama T, et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012;45(3):1121–8.

    Article  PubMed  CAS  Google Scholar 

  92. Hideyama T, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci. 2010;30(36):11917–25.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  93. Aizawa H, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010;120(1):75–84.

    Article  PubMed  CAS  Google Scholar 

  94. Yamashita T, et al. Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons. Sci Rep. 2017;7:39994.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Yamashita T, Akamatsu M, Kwak S. Altered intracellular milieu of ADAR2-deficient motor neurons in amyotrophic lateral sclerosis. Genes (Basel). 2017;8(2):pii: E60.

    Article  CAS  Google Scholar 

  96. Aizawa H, et al. Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUSP525L mutation. J Clin Neurosci. 2016;32:128–9.

    Article  PubMed  CAS  Google Scholar 

  97. D’Erchia AM, et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci Rep. 2017;7(1):10046.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Donnelly CJ, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415–28.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Bates GP, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.

    Article  PubMed  Google Scholar 

  100. Olney JW, de Gubareff T. Glutamate neurotoxicity and Huntington’s chorea. Nature. 1978;271(5645):557–9.

    Article  PubMed  CAS  Google Scholar 

  101. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature. 1976;263(5577):517–9.

    Article  PubMed  CAS  Google Scholar 

  102. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature. 1976;263(5574):244–6.

    Article  PubMed  CAS  Google Scholar 

  103. Beal MF. Huntington’s disease, energy, and excitotoxicity. Neurobiol Aging. 1994;15(2):275–6.

    Article  PubMed  CAS  Google Scholar 

  104. Paschen W, Hedreen JC, Ross CA. RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue. J Neurochem. 1994;63(5):1596–602.

    Article  PubMed  CAS  Google Scholar 

  105. Fourie C, et al. Differential changes in postsynaptic density proteins in postmortem Huntington’s disease and Parkinson’s disease human brains. J Neurodegener Dis. 2014;2014:938530.

    PubMed  PubMed Central  CAS  Google Scholar 

  106. Garrett E, Alexander M. Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci. 2004;6(3):259–80.

    Google Scholar 

  107. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76.

    Article  PubMed  CAS  Google Scholar 

  108. Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson’s disease: targets for potential treatments. Transl Neurodegener. 2017;6:28.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379–87.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Labbe C, Lorenzo-Betancor O, Ross OA. Epigenetic regulation in Parkinson’s disease. Acta Neuropathol. 2016;132(4):515–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Paz-Yaacov N, et al. Adenosine-to-inosine RNA editing shapes transcriptome diversity in primates. Proc Natl Acad Sci U S A. 2010;107(27):12174–9.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Wettengel J, et al. Harnessing human ADAR2 for RNA repair – recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res. 2017;45(5):2797–808.

    PubMed  CAS  Google Scholar 

  113. Chen T, et al. Genetic and epigenetic mechanisms of epilepsy: a review. Neuropsychiatr Dis Treat. 2017;13:1841–59.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Wang J, et al. Epilepsy-associated genes. Seizure. 2017;44:11–20.

    Article  PubMed  CAS  Google Scholar 

  115. Brusa R, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science. 1995;270(5242):1677–80.

    Article  PubMed  CAS  Google Scholar 

  116. Hu RQ, et al. Gamma-hydroxybutyric acid-induced absence seizures in GluR2 null mutant mice. Brain Res. 2001;897(1–2):27–35.

    Article  PubMed  CAS  Google Scholar 

  117. Kortenbruck G, et al. RNA editing at the Q/R site for the glutamate receptor subunits GLUR2, GLUR5, and GLUR6 in hippocampus and temporal cortex from epileptic patients. Neurobiol Dis. 2001;8(3):459–68.

    Article  PubMed  CAS  Google Scholar 

  118. Kitaura H, et al. Ca(2+)-permeable AMPA receptors associated with epileptogenesis of hypothalamic hamartoma. Epilepsia. 2017;58(4):e59–63.

    Article  PubMed  CAS  Google Scholar 

  119. Srivastava PK, et al. Genome-wide analysis of differential RNA editing in epilepsy. Genome Res. 2017;27(3):440–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  120. RAB JN, Allen SG, Fujikawa DG, Wasterlain CG. Hypoxic neuronal necrosis: protein synthesisindependent activation of a cell death program. PNAS. 2003;100(5):2825–30.

    Article  CAS  Google Scholar 

  121. Saver JL. Time is brain—quantified. Stroke. 2006;37(1):263–6.

    Article  PubMed  Google Scholar 

  122. Vilela P, Rowley HA. Brain ischemia: CT and MRI techniques in acute ischemic stroke. Eur J Radiol. 2017;96:162–72.

    Article  PubMed  Google Scholar 

  123. Khoshnam SE, et al. Pathogenic mechanisms following ischemic stroke. Neurol Sci. 2017;38(7):1167–86.

    Article  PubMed  Google Scholar 

  124. Peng PL, et al. ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron. 2006;49(5):719–33.

    Article  PubMed  CAS  Google Scholar 

  125. Liu S, et al. Expression of ca(2+)-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neuron. 2004;43(1):43–55.

    Article  PubMed  Google Scholar 

  126. Ahuja CS, et al. Traumatic spinal cord injury. Nat Rev Dis Primers. 2017;3:17018.

    Article  PubMed  Google Scholar 

  127. Ahuja CS, et al. Traumatic spinal cord injury-repair and regeneration. Neurosurgery. 2017;80(3S):S9–S22.

    Article  PubMed  Google Scholar 

  128. Di Narzo AF, et al. Decrease of mRNA editing after spinal cord injury is caused by down-regulation of ADAR2 that is triggered by inflammatory response. Sci Rep. 2015;5:12615.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  129. Murray KC, et al. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med. 2010;16(6):694–700.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  130. Huang YJ, Lane HY, Lin CH. New treatment strategies of depression: based on mechanisms related to neuroplasticity. Neural Plast. 2017;2017:4605971.

    PubMed  PubMed Central  Google Scholar 

  131. Palacios JM, Pazos A, Hoyer D. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology. 2017;234(9–10):1395–418.

    Article  PubMed  CAS  Google Scholar 

  132. Lin SH, Lee LT, Yang YK. Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin Psychopharmacol Neurosci. 2014;12(3):196–202.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  133. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Baxter G, et al. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci. 1995;16(3):105–10.

    Article  PubMed  CAS  Google Scholar 

  135. Sergeeva OA, Amberger BT, Haas HL. Editing of AMPA and serotonin 2C receptors in individual central neurons, controlling wakefulness. Cell Mol Neurobiol. 2007;27(5):669–80.

    Article  PubMed  CAS  Google Scholar 

  136. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083–152.

    Article  PubMed  CAS  Google Scholar 

  137. Lyddon R, et al. Serotonin 2c receptor RNA editing in major depression and suicide. World J Biol Psychiatry. 2013;14(8):590–601.

    Article  PubMed  Google Scholar 

  138. Kubota-Sakashita M, et al. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia. Mol Brain. 2014;7:5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  139. Park TM, Haning WF III. Stimulant use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(3):461–71.

    Article  PubMed  Google Scholar 

  140. Mathuru AS. A little rein on addiction. Semin Cell Dev Biol. 2017. https://doi.org/10.1016/j.semcdb.2017.09.030.

  141. Lopez-Quintero C, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on alcohol and related conditions (NESARC). Drug Alcohol Depend. 2011;115(1–2):120–30.

    Article  PubMed  Google Scholar 

  142. Everitt BJ. Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories—indications for novel treatments of addiction. Eur J Neurosci. 2014;40(1):2163–82.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Carr KD, et al. AMPA receptor subunit GluR1 downstream of D-1 dopamine receptor stimulation in nucleus accumbens shell mediates increased drug reward magnitude in food-restricted rats. Neuroscience. 2010;165(4):1074–86.

    Article  PubMed  CAS  Google Scholar 

  144. Zheng D, et al. Nucleus accumbens AMPA receptor involvement in cocaine-conditioned place preference under different dietary conditions in rats. Psychopharmacology. 2015;232(13):2313–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  145. Schmidt HD, et al. ADAR2-dependent GluA2 editing regulates cocaine seeking. Mol Psychiatry. 2015;20(11):1460–6.

    Article  PubMed  CAS  Google Scholar 

  146. Deborah L, Christensen P, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years – autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR. 2016;65(3):1–23.

    Article  Google Scholar 

  147. Park HR, et al. A short review on the current understanding of autism spectrum disorders. Exp Neurobiol. 2016;25(1):1–13.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Eran A, et al. Comparative RNA editing in autistic and neurotypical cerebella. Mol Psychiatry. 2013;18(9):1041–8.

    Article  PubMed  CAS  Google Scholar 

  149. Shamay-Ramot A, et al. Fmrp interacts with adar and regulates RNA editing, synaptic density and locomotor activity in zebrafish. PLoS Genet. 2015;11(12):e1005702.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  150. Feng Y, et al. Altered RNA editing in mice lacking ADAR2 autoregulation. Mol Cell Biol. 2006;26(2):480–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  151. Bahn JH, et al. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 2012;22(1):142–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  152. Wang C, et al. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett. 2017;411:27–34.

    Article  PubMed  CAS  Google Scholar 

  153. Maas S, et al. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 2001;98(25):14687–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  154. Paz N, et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007;17(11):1586–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  155. Galeano F, et al. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene. 2013;32(8):998–1009.

    Article  PubMed  CAS  Google Scholar 

  156. Cenci C, et al. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem. 2008;283(11):7251–60.

    Article  PubMed  CAS  Google Scholar 

  157. Choudhury Y, et al. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest. 2012;122(11):4059–76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  158. Cesarini V, et al. ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids Res. 2017;46(4):2045–59.

    Article  PubMed Central  Google Scholar 

  159. Paul D, et al. A-to-I editing in human miRNAs is enriched in seed sequence, influenced by sequence contexts and significantly hypoedited in glioblastoma multiforme. Sci Rep. 2017;7(1):2466.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Ileana Lorenzini and Stephen Moore contributed equally to this work.

Authors and Affiliations

  1. Barrow Neurological Institute, Department of Neurobiology, Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA

    Ileana Lorenzini & Stephen Moore

  2. Interdisciplinary Graduate Program in Neuroscience, Arizona State University, Tempe, AZ, USA

    Stephen Moore

  3. Department of Neurobiology and Neurology, Dignityhealth St. Joseph’s Hospital, Barrow Neurological Institute, Phoenix, AZ, USA

    Rita Sattler

Authors
  1. Ileana Lorenzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rita Sattler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rita Sattler .

Editor information

Editors and Affiliations

  1. Department of Neurobiology and Neurology, Dignityhealth St. Joseph’s Hospital, Barrow Neurological Institute, Phoenix, Arizona, USA

    Rita Sattler

  2. Department of Neurobiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    Christopher J. Donnelly

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lorenzini, I., Moore, S., Sattler, R. (2018). RNA Editing Deficiency in Neurodegeneration. In: Sattler, R., Donnelly, C. (eds) RNA Metabolism in Neurodegenerative Diseases. Advances in Neurobiology, vol 20. Springer, Cham. https://doi.org/10.1007/978-3-319-89689-2_3

Download citation

Publish with us

Policies and ethics

Search

Navigation